Two studies showed that administration of the TNF-α receptor antagonist etanercept did not seem to have any effect on the glucose-stimulated insulin response or reduced insulin resistance [10, 22], while treatment with infliximab, an anti-TNF-α antibody, may improve insulin sensitivity in patients with rheumatoid arthritis [23, 24]. Here, INS is linked to rheumatoid arthritis.